Velcera Announces Results From Two Canine Allergy Studies

Published: Jan 30, 2008

YARDLEY, PA--(Marketwire - January 29, 2008) - Velcera, Inc. (OTCBB: VLCR), a specialty pharmaceutical company focused on pet health, announced today the results of two studies on Promistâ„¢-VEL502 as a treatment for the clinical signs of canine allergy. Canine allergy is one of the most common complaints of dog owners and manifests itself in the form of a skin irritation which causes the animal to scratch. Promistâ„¢-VEL502 is Velcera's second product in development based on its patented Promist drug delivery system, which provides a metered dose liquid mist inside the oral cavity for systemic absorption and avoids the need for pets to swallow tablets or liquids.

Back to news